KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaboration Revenue BreakdownCollaboration Revenue Breakdown AnnualContractual ObligatonsCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Provision For Income TaxNon Gaap ExpensesNon Gaap Expenses AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue Breakdown AnnualProfitabilityProperty And Equipment, Net BreakdownRevenue By ProductRevenue By Product %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Pmo Product Revenues, Net BreakdownTotal Pmo Product Revenues, Net Breakdown Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Gross Profit (2016 - 2025)

Sarepta Therapeutics has reported Gross Profit over the past 9 years, most recently at $44.2 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 91.59% year-over-year to $44.2 million; the TTM value through Dec 2025 reached $1.4 billion, down 14.17%, while the annual FY2025 figure was $1.4 billion, 14.17% down from the prior year.
  • Gross Profit for Q4 2025 was $44.2 million at Sarepta Therapeutics, down from $248.6 million in the prior quarter.
  • Over five years, Gross Profit peaked at $1.0 billion in Q4 2023 and troughed at -$17.5 million in Q3 2022.
  • A 5-year average of $286.0 million and a median of $214.0 million in 2022 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: surged 20526.66% in 2021 and later plummeted 110.75% in 2022.
  • Year by year, Gross Profit stood at $169.7 million in 2021, then skyrocketed by 339.68% to $746.2 million in 2022, then skyrocketed by 38.56% to $1.0 billion in 2023, then plummeted by 49.12% to $526.1 million in 2024, then crashed by 91.59% to $44.2 million in 2025.
  • Business Quant data shows Gross Profit for SRPT at $44.2 million in Q4 2025, $248.6 million in Q3 2025, and $458.5 million in Q2 2025.